The quantitative result comes from counting fluorescence-positive and fluorescence-negative droplets after amplification. Positive droplets indicate that the target sequence was amplified, whereas negative droplets provide the complementary measurement needed for statistical estimation. Applying a Poisson distribution to these counts converts the observed pattern into an estimate of the original target copy number, rather than a simple signal intensity.
Partitioning makes concentration differences easier to resolve because the sample is assessed across many separate reaction chambers. This supports detection when a target is present at low abundance or mixed with complex material. In cancer studies, that sensitivity is particularly useful for identifying rare mutation signals, copy-number changes, or circulating tumor DNA within the broader nucleic-acid sample.
Fluorescence supplies the classification used for downstream quantification. After thermal cycling, each droplet is assigned as containing an amplified target or not, and the balance between these categories determines the statistical estimate. Consequently, interpretation depends on analyzing the complete positive-and-negative droplet pattern rather than considering only droplets that display a fluorescence signal.
Cancer samples may contain targets at very different concentrations, making small differences relevant to biomarker analysis. Microdroplet PCR addresses this need by tolerating small concentration differences and producing a quantitative copy-number estimate. That combination supports measurements involving rare mutations, circulating tumor DNA, and molecular changes followed during treatment.
An assay proceeds from partitioning the DNA sample into droplets to thermal cycling, followed by fluorescence-based droplet assessment. The post-cycling readout separates droplets with amplified target sequences from those without them. Statistical analysis then uses both groups to estimate starting copy number, linking the reaction steps to a quantitative nucleic-acid result.
In cancer research, the resulting measurements can address whether a rare mutation is detectable, whether a copy-number change is present, and whether circulating tumor DNA can be measured in a complex sample. The same analytical approach also supports treatment monitoring and minimal residual disease assessment, where sensitive biomarker measurements are important.